A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
RecruitingNCT06466525
Longevity Biotech Australia Pty Ltd (subsidiary)Parkinson Disease
Start: 2024-07-16End: 2027-02-01Target: 64Updated: 2026-08-21